{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"117.0"},{"groupId":"OG001","spread":"18.4","value":"87.7"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"6"},{"groupId":"OG002","value":"0"}],"units":"Participants"}],"title":"Baseline"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"5.7","value":"97.0"},{"groupId":"OG001","spread":"13.4","value":"89.4"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"9"},{"groupId":"OG002","value":"0"}],"units":"Participants"}],"title":"Prior to Maintenance Therapy"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"13.2","value":"90.0"},{"groupId":"OG001","spread":"14.4","value":"95.3"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"14"},{"groupId":"OG002","value":"0"}],"units":"Participants"}],"title":"Completion of Therapy"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"11.4","value":"94.8"},{"groupId":"OG001","spread":"19.9","value":"86.1"},{"groupId":"OG002","spread":"1.4","value":"87.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"21"},{"groupId":"OG002","value":"2"}],"units":"Participants"}],"title":"12 Months Off Therapy"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"9.7","value":"98.8"},{"groupId":"OG001","spread":"20.6","value":"82.5"},{"groupId":"OG002","spread":"4.6","value":"90.8"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"26"},{"groupId":"OG002","value":"4"}],"units":"Participants"}],"title":"24 Months Off Therapy"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"13.3","value":"100.2"},{"groupId":"OG001","spread":"24.9","value":"88.1"},{"groupId":"OG002","spread":"14.9","value":"81.4"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"12"},{"groupId":"OG001","value":"27"},{"groupId":"OG002","value":"5"}],"units":"Participants"}],"title":"36 Months Off Therapy"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"16.0","value":"77.1"},{"groupId":"OG001","spread":"16.0","value":"88.7"},{"groupId":"OG002","spread":"15.0","value":"95.7"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"13"},{"groupId":"OG001","value":"25"},{"groupId":"OG002","value":"3"}],"units":"Participants"}],"title":"48 Months Off Therapy"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"22.1","value":"81.9"},{"groupId":"OG001","spread":"16.4","value":"87.9"},{"groupId":"OG002","spread":"23.7","value":"70.3"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"14"},{"groupId":"OG001","value":"18"},{"groupId":"OG002","value":"3"}],"units":"Participants"}],"title":"60 Months Off Therapy"}],"denoms":[{"counts":[{"groupId":"OG000","value":"25"},{"groupId":"OG001","value":"50"},{"groupId":"OG002","value":"10"}],"units":"Participants"}],"description":"Scores measuring verbal fluency were obtained from Retrieval Fluency standard scores on the Woodcock Johnson III instrument. Higher scores indicate better performance. The normative mean is 100 with a standard deviation of 15.","dispersionType":"Standard Deviation","groups":[{"description":"Patients with gross total resection (GTR)/no evidence of metastatic (M0) medulloblastoma, nodular desmoplastic or high grade glioma histology will receive induction chemotherapy and low-risk therapy.","id":"OG000","title":"Low-Risk Group"},{"description":"Patients with M0 medulloblastoma or nodular desmoplastic histology with less than a GTR, other histologic diagnoses with no metastatic disease, will receive induction chemotherapy and intermediate-risk therapy.","id":"OG001","title":"Intermediate-Risk Group"},{"description":"Patients with central nervous system (CNS) metastatic disease will receive induction chemotherapy and high-risk therapy.","id":"OG002","title":"High-Risk Group"}],"paramType":"MEAN","populationDescription":"Eligible patients with scores at any of the data collection timepoints were included. Sample sizes differ across timepoints as not all subjects had scores for all timepoints.","reportingStatus":"POSTED","timeFrame":"Baseline, prior to maintenance therapy, completion of therapy, and 12 months, 24 months, 36 months, 48 months, and 60 months off therapy","title":"Neurocognitive Performance Related to Verbal Fluency as Measured by Retrieval Fluency Standard Scores","type":"SECONDARY","unitOfMeasure":"score on a scale"}